Safety and Effectiveness of TactiCath™ Contact Force, Sensor Enabled™ (TactiCath SE) Catheter for Ablation of Drug Refractory, Symptomatic, Persistent Atrial Fibrillation

NACompletedINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

September 28, 2018

Primary Completion Date

December 21, 2020

Study Completion Date

January 11, 2021

Conditions
Persistent Atrial Fibrillation
Interventions
DEVICE

TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™

Ablation procedure for Persistent AF

Trial Locations (22)

3050

Royal Melbourne Hospital - City Campus, Parkville

5000

Royal Adelaide Hospital, Adelaide

10016

New York University Hospital, New York

21287

Johns Hopkins University Hospital, Baltimore

29425

Medical University of South Carolina, Charleston

30322

Emory University Hosptial, Atlanta

32803

Florida Hospital, Orlando

35249

University Hospital (UAB), Birmingham

39216

Jackson Heart Clinic, Jackson

44195

The Cleveland Clinic Foundation, Cleveland

63110

Barnes-Jewish Hospital, St Louis

68506

Bryan Heart, Lincoln

70121

Ochsner Medical Center, New Orleans

72211

Arkansas Heart Hosptial, Little Rock

72401

St. Bernards, Jonesboro

75093

The Heart Hospital Baylor Plano, Plano

78705

Texas Cardiac Arrhythmia, Austin

80120

South Denver Cardiology Associates, Littleton

92037

Scripps Health, La Jolla

94062

Sequoia Hospital, Redwood City

02114

Massachusetts General Hospital, Boston

07753

Jersey Shore University Medical Center, Neptune City

Sponsors
All Listed Sponsors
lead

Abbott Medical Devices

INDUSTRY